Vyne Therapeutics Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.vynetherapeutics.com

Moat Score

Market Cap $39.53M
PE -1
Debt $0.00
Cash $16.32M
EV $23.21M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$34.00M
EBIT	-$33.95M
ROE	-54%
ROA	-45%
Equity	$63.54M
Growth Stability	1
PE	-1.16
PB	0.62
P/S	80.19
Price/Cash	0.41
Debt/Equity	0
Net Margins	-7K%
Op. Margins	-7K%
Sales Growth YoY	6%
Sales Growth QoQ	-39%
Sales CAGR	-13%
Equity CAGR	-17%
Earnings Growth YoY	85%
Earnings Growth QoQ	29%

Sales CAGR 5Y	-63%
Equity CAGR 5Y	-9%
Earnings CAGR 3Y	-73%
Sales CAGR 3Y	-73%
Equity CAGR 3Y	15%
Market Cap	$39.53M
Revenue	$493.00K
Assets	$76.20M
Total Debt	$0.00
Cash	$16.32M
Shares Outstanding	14.75M
EV	23.21M
Moat Score	1%
Working Capital	60.87M
Current Ratio	5.81
Shares Growth 3y	21%
Equity Growth QoQ	-15%
Equity Growth YoY	452%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds.

SEC Filings

Direct access to Vyne Therapeutics Inc. (VYNE) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vyne Therapeutics Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vyne Therapeutics Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vyne Therapeutics Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vyne Therapeutics Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-2K%	-635%	-	-	-1K%	-497%	-5K%	-7K%	-7K%
ROA	-	-34%	-44%	-39%	-96%	-269%	118%	57%	-29%	-45%
ROE	-	48%	51%	-39%	-108%	-682%	-151%	-74%	-32%	-54%

Bad Net Margins (-6.67K%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-0.5	-0.24	-0	-	-	-
Debt over Equity	-	-	-	-	0.48	0.88	0	0	0	0
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	580%	-100%	-	-	-30%	-97%	-11%	-63%
Earnings YoY growth	-	205%	107%	77%	43%	247%	-71%	-68%	23%	-
Equity YoY growth	-	85%	94%	-329%	-47%	-45%	30%	-36%	184%	-9%
FCF YoY growth	-	-44%	1K%	87%	23%	111%	-59%	-	-	-